A common way to prevent infectious viral diseases, such as COVID-19 and the flu, is to the virus that causes them. Vaccines can be made from a virus's proteins or other parts, has been inactivated and is no longer harmful. Some vaccines, such as the flu vaccine, n every year to keep up with changes in the virus. Studies have shown that SARS-CoV-2 has a slower mutation rate than the influenza viru: flu. This means that mutations occur less frequently in SARS-CoV-2's genome than in the genome. Scientists at Arizona State University sequenced SARS-CoV-2 genomes collected from h infected individuals. They found a deletion of 81 nucleotides in some of the viruses. This in a gene that codes for a protein that helps the virus escape the immune system. 8. Predict how the frequency of viruses with this deletion will change in the population Use evidence to support your answer.

A common way to prevent infectious viral diseases, such as COVID-19 and the flu, is to the virus that causes them. Vaccines can be made from a virus's proteins or other parts, has been inactivated and is no longer harmful. Some vaccines, such as the flu vaccine, n every year to keep up with changes in the virus. Studies have shown that SARS-CoV-2 has a slower mutation rate than the influenza viru: flu. This means that mutations occur less frequently in SARS-CoV-2's genome than in the genome. Scientists at Arizona State University sequenced SARS-CoV-2 genomes collected from h infected individuals. They found a deletion of 81 nucleotides in some of the viruses. This in a gene that codes for a protein that helps the virus escape the immune system. 8. Predict how the frequency of viruses with this deletion will change in the population Use evidence to support your answer.

Human Physiology: From Cells to Systems (MindTap Course List)

9th Edition

ISBN:9781285866932

Author:Lauralee Sherwood

Publisher:Lauralee Sherwood

Chapter12: Body Defenses

Section: Chapter Questions

Problem 2TAHL

See similar textbooks

Similar questions

People infected with SARS-Cov-2(the cornavirus that causes covid-19) can show an array of different symptoms and comlications. One complication occurs in the same patients is the development of blood clots throughout the body. Thevirus can infect endothelial cells. How are endothelia involved with blood clotting? If you were to design a pharmaceutical (medication) taht reduced blood clotting, how might it work? There are many ways to approach this question. Please mention at least one SPECIFIC REACTION in your explanation.
Many pharmaceutical companies are trying to produce vaccine against Corona virus (COVID-19) but they are facing problems to find an effective, safe and universal vaccine. Explain
The best way to end the pandemic is to get vaccinated. However, considering that there isnot enough human trial to determine its efficacy, is getting COVID 19 vaccine worth therisk? Supposed you opted to take risk to be vaccinated, is it an egoistic or altruistic choice?Justify your moral position.
When an antibody binds to the spike protein of SARS-CoV-2, it may block access of the spike protein to the ACE2 protein on human cells. This is one way an antibody can prevent the virus from attaching to and getting inside of human cells. But antibodies can do more than just block virus entry. Due to the symmetrical structure of the immunoglobulin molecule, it can bind to two antigen molecules simultaneously, like this: As a result, antibodies can cross-link multiple viruses in a three-dimensional network. Using this diagram as a starting point, draw several additional viruses and antibodies to illustrate what a cross-linked antigen-antibody complex might look like.
Viruses can easily mutate exchange genetic material, mechanisms referred to as antigenic drift and antigenic shift. These changes allow the virus to evade the immune system defenses. Match each term with the correct definition Antigenic drift [ Choose ] [Choose ] Different strains of a virus or strain of different viruses, combine and form a new strain that now has a mixture of the surface antigens Antigenic shift The virus changes genetically by accumulating mutations within the genes that code for antibody-binding sites
From: "Towards a universal flu vaccine" Researchers are trying to create a universal influenza vaccine - one that can confer immunity to all, or nearly all, strains of influenza virus. The universal vaccine will target a stable antigen that is present on all influenza viruses that does not readily mutate to different forms. The target researchers are focusing on as a universal stable antigen is on the... O The H spike head. O H spike neck O N spike O Viral envelope
Many pharmaceutical companies are trying to produce vaccine against Corona virus (COVID-19) but they are facing problems to find an effective, safe and universal vaccine.
A few years ago, Ebola was all over the news and it looks like it may return. A treatment method developed during the last outbreak involved patients who have recovered and then donated plasma to patients fighting an active infection. It is a remarkable treatment, with potential ethical dilemmas. Now, many people are attempting to turn to convalescent plasma treatments in lieu of vaccinations. There are articles on both Ebola and COVID-10 convalescent plasma use. Read the articles below, feel free to do more research on your own on the topic. Using the information in the lesson, the articles, and your own research, answer the following questions: 1) What are the potential ethical issues for donors, recipients, and medical providers? 2) What rules and stipulations should be applied to it's use, given that there is a limited supply for use in treatment? 3) Would you use this treatment for yourself or a loved one? Assigned Reading: Katz, L.M. (2021). (A little) clarity on…
The process by which point mutations cause slight changes in the spike proteins hemagglutinin and neuraminidase of the influenza virus is called O antigenic drift O tranformation O antigenic shift O transduction
The majority of vaccines work by eliciting pathogen-specific antibodies that circulate in our bodies and protect us in the event that we are later exposed to that specific pathogen. For most viruses and bacterial toxins that we are vaccinated against, these pre-existing antibodies are protective because They induce mucus production that helps flush the toxin or virus out of the body They bind to the virus or toxin and carry it to the liver where it can be degraded O They neutralize the virus or toxin, preventing it from attaching to and entering our cells They bind to epithelial cells and induce the production of antimicrobial peptides
An individual was simultaneously infected with the HIN1 strain of flue and the H5N2 strain of the flu. The viruses recombined to produce an H5N1 strain Which process occuned en ths ndvidia O Antigenic shih O Antigenic dn O Crossing over O Frameshit mutation
During the development process of a vaccine for the newly discovered Sars-COV-2 (COVID- 19) virus, pharmaceutical companies developed two potential vaccine candidates, BNT162b2 and Ad26.COV2. Some researchers postulated that BNT162b2 will be more ef- fective than Ad26.COV2 because only BNT162b2 directly targets the protein-manufactur- ing mechanisms in the cell. To test this claim, researchers proposed an experiment in which data will be collected about the efficacy of the two vaccine candidates. In the proposed study, two groups of mice will be randomly assigned one of the vaccine candidates and then infected with the virus. Data about the severity of symptoms in each group will then be collected. Which of the following describes a potential method for measuring the dependent variable in this experimental design? A B с D measure the amount of virus administered to each group measure the time between vaccine administration and virus infection in each group measure the amount of vaccine…